JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Order Through VWR & Receive a FREE Sample

Support: [email protected]

Track Your Order

Home
Bioactive Compounds
Signaling Pathways

Signaling Pathways

A2606 Epoxomicin
25 Citation

Summary: proteasome inhibitor

≥27.73 mg/mL
A4112 Barasertib (AZD1152-HQPA)
6 Citation

Target: Aurora Kinases

Summary: Aurora Kinase B inhibitor, Potent and selective

≥25.4 mg/mL
A4113 ZM 447439
2 Citation

Target: Aurora Kinases|MEK|Src|Lck

Summary: Aurora Kinase inhibitor,potent and selective

≥25.7 mg/mL
A4129 ENMD-2076 L-(+)-Tartaric acid

Summary: Aurora kinases inhibitor

insoluble in EtOH; ≥175.8 mg/mL
A4130 ENMD-2076

Target: Aurora Kinases|FLT3|RET|Src|VEGFR3/FLT4|NTRK1/TRKA|CSF-1R/c-Fms

Summary: Selective Aurora A/Flt3 inhibitor

insoluble in H2O; ≥18.75 mg/mL
A4132 CCT137690

Target: Aurora Kinases

Summary: Aurora A/B/C inhibitor

insoluble in H2O; insoluble in EtOH; ≥6.89 mg/mL
A4024 Danoprevir (RG7227)

Target: HCV Proteases

Summary: HCV NS3/4A protease inhibitor

≥32.6 mg/mL
A8204 Lopinavir

Summary: HIV protease inhibitor,highly potent

≥31.45 mg/mL
A4031 Telaprevir (VX-950)
1 Citation

Target: HCV NS3-4A protease

Summary: HCV NS3-4A protease inhibitor

≥32.95 mg/mL
A4032 VX-222 (VCH-222, Lomibuvir)

Target: HCV polymerase

Summary: NNI of HCV RNA polymerase

≥44.6 mg/mL